Remove 2012 Remove RNA Remove Therapies
article thumbnail

Leveraging ADCs in precision oncology strategy

Drug Target Review

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? Patient specific treatment plans can be tailored to the cohorts that express the targets including feasibility assessment of combinations of our ADC targets with other lines of therapy.

article thumbnail

ViiV Healthcare Announces Analysis Showing no Antiretroviral Therapy Interruptions Due to COVID-19 Across its Clinical Development Programme for Investigational, Long-Acting Cabotegravir and Rilpivirine

The Pharma Data

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

Neutralising GDF-15 with CatalYm’s anti-GDF-15 antibody visugromab was shown to reverse its inhibitory effects and to re-sensitise tumours to anti-PD-1 treatment, achieving commensurate survival benefit of anti-GDF-15-anti-PD-1 combination therapy in vivo. 2012 Feb 1;24(1):107-15. in North America) in late 2017. Biophysical Journal.

article thumbnail

Clinical Catch-Up: January 4-8 | BioSpace

The Pharma Data

FBX-101 is a first-in-human AAV gene therapy. Precigen received the okay from the FDA to initiate a Phase I trial of PRGN-2012 in recurrent respiratory papillomatosis (RRP). The drug is an RNA interference (RNAi) therapeutic. The primary endpoint was progression-free survival (PFS) by blinded independent review. Most Read Today.

article thumbnail

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

The Pharma Data

The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. Shionogi joined in October 2012. At the conclusion of the study, the largest mean changes in viral load were -1.5 log 10 and -2.0

article thumbnail

Developing an mRNA therapy for Duchenne muscular dystrophy

Drug Target Review

There are a few approved therapies for DMD including four exon-skipping drugs and one AAV-microdystrophin drug, which uses a shortened version of dystrophin. AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. Of note, mRNA is redosable as opposed to AAV. Human molecular genetics.

article thumbnail

Could illuminating the surfaceome help find new targeted cancer therapies?

Drug Target Review

To date, there are less than 30 known surface proteins that form the basis of all approved cancer-targeted therapies of all modalities, including antibody-drug conjugates (ADCs), T-cell engagers, CAR T-cells and radiopharmaceuticals. These could be targets for antibody-drug conjugates (ADCs), bi-specific antibodies, or other therapies.